PubRank

Andrew Spaltenstein

Author PubWeight™ 19.75‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir. Antimicrob Agents Chemother 2004 1.17
2 Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385. Bioorg Med Chem Lett 2006 1.15
3 Potent inhibitors of the HIV-1 protease incorporating cyclic urea P1-P2 scaffold. Bioorg Med Chem Lett 2004 1.00
4 New, potent P1/P2-morpholinone-based HIV-protease inhibitors. Bioorg Med Chem Lett 2006 0.96
5 In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV. Antimicrob Agents Chemother 2007 0.94
6 Amine substituted N-(1H-benzimidazol-2ylmethyl)-5,6,7,8-tetrahydro-8-quinolinamines as CXCR4 antagonists with potent activity against HIV-1. Bioorg Med Chem Lett 2009 0.92
7 Synthesis and SAR of novel isoquinoline CXCR4 antagonists with potent anti-HIV activity. Bioorg Med Chem Lett 2010 0.87
8 Novel 4,4-disubstituted piperidine-based C-C chemokine receptor-5 inhibitors with high potency against human immunodeficiency virus-1 and an improved human ether-a-go-go related gene (hERG) profile. J Med Chem 2011 0.85
9 Hepatitis C replication inhibitors that target the viral NS4B protein. J Med Chem 2013 0.83
10 Blockade of X4-tropic HIV-1 cellular entry by GSK812397, a potent noncompetitive CXCR4 receptor antagonist. Antimicrob Agents Chemother 2009 0.83
11 Inhibition of wild-type and mutant human immunodeficiency virus type 1 proteases by GW0385 and other arylsulfonamides. Biochemistry 2004 0.82
12 Novel arylsulfonamides possessing sub-picomolar HIV protease activities and potent anti-HIV activity against wild-type and drug-resistant viral strains. Bioorg Med Chem Lett 2004 0.82
13 Discovery of potent pyrrolidone-based HIV-1 protease inhibitors with enhanced drug-like properties. Bioorg Med Chem Lett 2004 0.82
14 Optimization of pyrrolidinone based HIV protease inhibitors. Bioorg Med Chem Lett 2005 0.80
15 Synthesis and antiviral activities of novel N-alkoxy-arylsulfonamide-based HIV protease inhibitors. Bioorg Med Chem Lett 2005 0.79
16 Novel P1 chain-extended HIV protease inhibitors possessing potent anti-HIV activity and remarkable inverse antiviral resistance profiles. Bioorg Med Chem Lett 2005 0.78
17 Discovery of a potent boronic acid derived inhibitor of the HCV RNA-dependent RNA polymerase. J Med Chem 2013 0.78
18 Tetrahydrocarbazole amides with potent activity against human papillomaviruses. Bioorg Med Chem Lett 2009 0.78
19 Synthesis of a novel tricyclic 1,2,3,4,4a,5,6,10b-octahydro-1,10-phenanthroline ring system and CXCR4 antagonists with potent activity against HIV-1. Bioorg Med Chem Lett 2010 0.78
20 Substituted tetrahydro-beta-carbolines as potential agents for the treatment of human papillomavirus infection. Bioorg Med Chem Lett 2009 0.77
21 Imidazopyridine-5,6,7,8-tetrahydro-8-quinolinamine derivatives with potent activity against HIV-1. Bioorg Med Chem Lett 2009 0.77
22 Novel N-substituted benzimidazole CXCR4 antagonists as potential anti-HIV agents. Bioorg Med Chem Lett 2010 0.76
23 Substituted tetrahydrocarbazoles with potent activity against human papillomaviruses. Bioorg Med Chem Lett 2009 0.76
24 Novel prodrug approach to amprenavir-based HIV-1 protease inhibitors via O-->N acyloxy migration of P1 moiety. Bioorg Med Chem Lett 2003 0.75
25 Discovery of N-benzyl-N'-(4-pipyridinyl)urea CCR5 antagonists as anti-HIV-1 agents (II): modification of the acyl portion. Bioorg Med Chem Lett 2010 0.75
26 Novel spirocyclic pyrrolidones as P2/P1 mimetics in potent inhibitors of HIV-1 protease. Bioorg Med Chem Lett 2002 0.75
27 Discovery of N-benzyl-N'-(4-pipyridinyl)urea CCR5 antagonists as anti-HIV-1 agents (I): optimization of the amine portion. Bioorg Med Chem Lett 2010 0.75